This article introduces Aragen Life Sciences Ltd., an Indian biopharmaceutical company. The company is a CRO (contract research organization) that provides in-house R&D services, including non-clinical trials, and its core business is CRDMO services, which provide comprehensive support from the concept stage to commercialization. The following is a survey and summary of the characteristics of the company's contract non-clinical testing services.
Aragen Life Sciences Ltd. provides in-house research and development services, including non-clinical trials. The company's core business is CRDMO services, which provide total support for new drugs from the idea stage to commercialization, and it has business relationships with a large number of companies. To support this business, Aragen Life Sciences Ltd. has a research facility in Pune, India. This facility is GLP (Good Laboratory Practices) and AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) certified, and is also in line with OECD (Organization for Economic Cooperation and Development) standards.
Aragen Life Sciences Ltd. offers a wide range of services for both Small Molecules and Large Molecules (Biologics). Non-clinical trials are mainly positioned as "safety evaluation" in the early stages of drug discovery. In particular, safety evaluation is listed as a core service along with integrated drug discovery, chemistry, and biology in the small molecule drug discovery services. This is indicative of the company's desire to incorporate non-clinical testing from the earliest stages of the drug discovery process, leading to more efficient development.
The company's non-clinical testing services are not limited to the pharmaceutical and biotech industries, but also serve the industrial chemical and agrochemical industries. The company's ability to serve such a diverse range of industries is due to its robust technical foundation and its expertise and flexibility in evaluating the safety of not only pharmaceuticals, but also a wide variety of chemicals and biotechnology products.
The company offers a variety of pathological models, one example being a model to advance research on glioblastoma (glioblastoma / GBM). This model allows for the study of the disease and the validation of treatments by injecting human glioblastoma cells into the brain of a thymus-free nude mouse to create a tumor, thus enabling the study of the disease in conditions similar to those of human disease.
In addition, various other models of inflammation and pain are available, including a CFA-induced inflammatory pain model using rats.
No specific case studies were available on the official website.
Aragen Life Sciences Ltd. has several offices in India as well as in the U.S., serving a variety of companies.
| Address | 28 A, IDA Nacharam Hyderabad 500 076, India |
|---|---|
| Tel | +91 40 6692 9999 |
| Website | https://www.aragen.com |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.